Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the use of Alocyte (cord blood plasma plus mononucleic
cells) will be safe, well tolerated, and whether it causes any side effects. The study will
also examine if the use of the Investigational Product (IP) is able to reduce local
inflammation or alleviate Facetogenic back pain